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HIV-1Antibodies neutralising porcine endogenous retroviruses (PERVs) were induced in different animal species by
immunisation with the transmembrane envelope protein p15E. These antibodies recognised epitopes,
designated E1, in the fusion peptide proximal region (FPPR) of p15E, and E2 in the membrane proximal
external region (MPER). E2 is localised in a position similar to that of an epitope in the transmembrane
envelope protein gp41 of the human immunodeﬁciency virus-1 (HIV-1), recognised by the monoclonal
antibody 4E10 that is broadly neutralising. To detect neutralising antibodies speciﬁc for PERV, a novel assay
was developed, which is based on quantiﬁcation of provirus integration by real-time PCR. In addition, for the
ﬁrst time, highly effective neutralising antibodies were obtained by immunisation with the surface envelope
protein of PERV. These data indicate that neutralising antibodies can be induced by immunisation with both
envelope proteins.l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Xenotransplantation using porcine cells or organs may offer a
potential solution to the shortage of human donor organs. Prior to the
clinical use of porcine xenotransplants, three main hurdles must be
taken: immunologic rejection, physiological incompatibility, and the
risk of transmission of porcine pathogens. Designated pathogen-free
breeding of pigs can prevent transmission of most porcine micro-
organisms. However, this is not possible in the case of porcine endo-
genous retroviruses (PERVs), which are integrated in the genome of
all pigs (Le Tissier et al., 1997), are released from normal pig tissues
(Wilson et al., 1998; Martin et al., 1998; Tacke et al., 2000), and infect
human cells at least in vitro (Patience et al., 1997; Specke et al.,
2001a). Although different strategies aimed at preventing PERV
transmission such as speciﬁc selection of animals expressing low
amounts of PERV (Tacke et al., 2003) or generation of animals ex-
pressing PERV-speciﬁc siRNA (Dieckhoff et al., 2008; Ramsoondar
et al., 2009) are under development, a preventive vaccine or passive
immunisation of the recipient may be useful. We described the
induction of neutralising antibodies by means of immunisation with
the ectodomain of the transmembrane envelope protein p15E of PERV
(Fiebig et al., 2003). Two epitopes were recognised by the serum—
one, designated E1, in the fusion peptide proximal region (FPPR) of
p15E, and another, E2, in the membrane proximal external region(MPER). Since there is no adequate animal model allowing analyses
of the efﬁcacy of PERV-speciﬁc neutralising antibodies in vivo,
immunisations with p15E of the closely related feline leukaemia
virus (FeLV) were performed in parallel. FeLV infects cats in vivo and
causes leukaemia and immunodeﬁciency. When rats, goats and cats
were immunised with the ectodomain of p15E of FeLV, neutralising
antibodies were easily induced and a similar epitope pattern as in the
case of PERV was observed (Langhammer et al., 2005, 2006). When
cats immunised with p15 alone were challenged with infectious FeLV,
protection from antigenemia was shown in 50% of the animals
(Langhammer et al., 2011), whereas all animals immunised with the
surface envelope protein gp70 alone or together with p15E were
protected (unpublished data). In an additional study, rats were
immunised with p15E of FeLV together with its recombinant surface
envelope protein gp70 and higher titres of neutralising antibodies
were obtained than in the case of immunisation with each antigen
alone (Langhammer et al., 2010). Immunotherapy studies in mice
infected with murine leukaemia virus (MuLV) showed a better
therapeutic effect when animals were treated with antibodies against
p15E and gp70 in combination (Schwarz et al., 1984). The investiga-
tion of successful vaccines against gammaretroviruses may have
implications for HIV vaccine research because of the structural and
functional similarity of all retroviral Env proteins. Interestingly, the
epitopes found in the MPER of FeLV and PERV are localised in
positions similar to that of the epitopes of 2F5 and 4E10, antibodies
broadly neutralising HIV-1. Despite the great evolutionary distance, a
limited sequence homology between the epitope sequences in the
transmembrane envelope protein gp41 of HIV-1 and p15E of PERV
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induce antibodies broadly neutralising HIV-1 have failed.
Here we conﬁrm and extend our previous report on neutralising
antibodies against PERV (Fiebig et al., 2003). We show generation of
antibodies recognising the MPER of p15E in four animal species.
The ability to induce such antibodies in different species indicates
that similar antibodies may be also induced in other species including
non-human primates and humans, if required. For the ﬁrst time,
neutralising antibodies speciﬁc for the surface envelope protein gp70
of PERV were induced. This allows performing immunisation studies
with a combination of surface and transmembrane envelope proteins.
Results
Production and characterisation of antigens used for immunisation
In order to produce recombinant antigens for immunisation, the
sequence of the ectodomain of p15E (amino acids 488–596, accession
number HQ688786), and of the surface envelope protein gp70 (amino
acids 49–487, accession number HQ688785) of PERV-A were
ampliﬁed by PCR. cDNA from PERV-producing PK-15 cells was used
as template. The fragments were cloned using the expression vectors
pCal-n or pET22b(+) (Fig. 1). After expression in Escherichia coli BL21,
p15E was puriﬁed by calmodulin binding protein and gp70 by His
tag afﬁnity chromatography. The recombinant p15E had a molecular
mass of 12 kDa (Fig. 2A). Recombinant gp70 comprises 439 amino
acids, the furin cleavage site is located at position 462, and the
recombinant protein contains the ﬁrst 25 amino acids of p15E in
addition to gp70. Therefore this protein corresponds to the recom-
binant surface envelope protein p45 of FeLV used in the commercial
vaccine Leucogen, which effectively protects cats from FeLV induced
disease and antigenemia (Hofmann-Lehmann et al., 1995). At the
N-terminus of the recombinant surface envelope protein of PERV, a
pelB leader sequence is attached to direct the protein into the
periplasma of E. coli producer cells. Constructs not containing this
leader sequence did not show expression (data not shown). Since the
pelB leader sequence was not cleaved, the recombinant surface
envelope protein had a molecular mass of 54 kDa as shown by SDS-
page analysis (Fig. 2A).
Induction and characterisation of binding antibody response
One goat (#62), 10 mice, 4 rats and two guinea pigs were im-
munised with the recombinant surface envelope protein gp70; three
goats (#16, #346 and #355), 10 mice, 9 rats in the ﬁrst experiment
and 4 rats in the second, as well as two guinea pigs were immunised
with the transmembrane envelope protein p15E. 10 mice, 4 rats and
two guinea pigs were immunised with both, gp70 and p15E, and 10
mice, two guinea pigs and 4 rats were immunised with adjuvant
alone. Goat #20 had been immunised previously with p15E (Fiebig
et al., 2003). Speciﬁc antibodies were detected in the sera of all theseA
B
C
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Fig. 1. Schematic presentation of the viral envelope proteins and antigens used for immunisat
AJ133817), protease cleavage sites (PCS) are marked with arrow heads, SP—signal peptide
N-terminal pelB leader sequence promoting translocation to the periplasma and a C-termi
(CBP) as expressed using the vector pCal-n.animals. The sera reacted with the recombinant antigens used for
immunisation (not shown) as well as with the viral protein in ELISAs
and Western blot analyses (Fig. 2A). The titres of the binding
antibodies as determined in ELISAs were in the range of 104 to 106,
similar to the titre of the goat serum against p15E reported previously
(Fiebig et al., 2003) (Fig. 2B). In parallel the responses against gp70
were analysed (Fig. 2C).Measurement of neutralisation by provirus integration using a PCR
In ﬁrst experiments, neutralisation was measured by provirus
integration using a PERV-speciﬁc PCR (Fiebig et al., 2003). The
neutralisation of PERV/5°, a high-titre recombinant PERV-A/C virus
infecting human 293 cells (Denner et al., 2003), and PERV-B, also
infecting human cells, was analysed. The viruses were titred in the
absence and presence of the immune serum and the TCID50 was
determined. Whereas the TCID50 of the virus in the absence of
immune serum was 104.31, it was reduced to up to 1% in the presence
of neutralising sera (Supplementary Table 1), indicating 99% neu-
tralisation at a serum dilution of 1:10. Two goat sera (#20, #16) and
9 rat sera were found to neutralise in this range. The sera did not
cross-neutralise HIV-1, MuLV and FeLV (not shown).Generation of a novel neutralisation assay based on measurement of
provirus integration using a duplex real-time PCR
To improve detection of PERV-speciﬁc neutralising antibodies in
the immune sera, a novel assay was established, which is based on
quantiﬁcation of the neutralising activity by measuring viral DNA in
the cells using a real-time PCR. Neutralisation was measured by
estimating the difference between provirus integration in control cells
(virus treated with medium or preimmune sera) and provirus
integration in cells incubated with virus treated with immune sera.
For this assay, also human 293 cells and PERV/5°, a PERV-A/C recom-
binant virus, were used. This new neutralisation assay also allows
detecting cytotoxic effects of the sera on target cells by measuring
the cellular gene GAPDH in parallel to the PERV provirus. Cytotoxic
effects that may lead to false-positive results may be expected when
the copy number of GAPDH is lower than in control samples. Since
primers and probe correspond to highly conserved regions in the gag
sequence, PERV-A, PERV-B and PERV-C could be detected in the assay.
This assay is universal, as all types of human cells that can be infected
by PERV may be used. If cells are used that can be infected by PERV
and by other retroviruses, e.g., HIV-1, virus-speciﬁcity of the immune
response can be analysed. When the efﬁciency of the duplex PCR
was analysed using serial dilutions of PERV and GAPDH in buffer or
human DNA, the slopes of the regression curves indicated efﬁciencies
of almost 100% (Fig. 3A, B). There was no interference between
both real-time PCRs, and the absolute detection limit was 10 copies of
PERV provirus in 25 μl reaction mix.HIS
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Fig. 3. Efﬁcacies of the duplex real-time PCRs used in the neutralisation assay. Dilutions
of PERV-A clone 220/14 (nearly 100% efﬁcacy) and of an hGAPDH plasmid (nearly 100%
efﬁcacy) were performed in buffer (A) and human DNA (B) and the ct values were
measured. (C) Neutralising activity of the goat serum 62, immunised with gp70, and
goat sera 346 and 355, immunised with p15E. In addition, the neutralising activity of
puriﬁed immunoglobulins from serum 355 was measured.
Fig. 2. (A) SDS-PAGE analysis of the recombinant antigens gp70 (54 kDa) and p15E
(12 kDa) puriﬁed by afﬁnity chromatography and Western blot analysis using puriﬁed
virus particles as antigen and selected immune sera from different species (3–7, goats;
8–10, rats; 11–13, guinea pigs; 14–16, mice) immunised with gp70 (7, 10, 13, 16), p15E
(3–6, 8, 11, 14) and a combination of gp70 and p15E (9, 12, 15). (B) Titres of antibodies
binding to gp70 after immunisation of one goat (#62), 16 rats, 8 guinea pigs, and 40
mice (pooled serum) as estimated by ELISA using recombinant gp70 as antigen. (D)
Titres of antibodies binding to p15E after immunisation of two goat (#346, #355), 3
rabbits, 16 rats, 8 guinea pigs, and 40 mice (pooled serum) as estimated by ELISA using
recombinant p15E as antigen. Black columns indicate sera from animals immunised
with p15E, gray with gp70, hatched with gp70 and p15E, and white with PBS.
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Sera from four goats immunisedwith p15E and the serum from the
goat immunised with gp70, but not the preimmune sera, showed
PERV-speciﬁc and dose dependent neutralisation (Fig. 3C). Puriﬁed
immunoglobulins isolated from these sera were also neutralising,
indicating that the neutralising activity was based on immunoglobu-
lins (Fig. 3C). The titre was determined by setting 2ct values above thehighest ct value of preimmune sera as cut off. The titre of goat serum
355 was 1:20, that of goat serum 346 1:40, that of the isolated
immunoglobulins from serum 355 was 1:40 at 0,75 mg/ml and that of
serum 62, speciﬁc for gp70, 1:320. Neutralising antibodies were also
induced in a ﬁrst experiment in 9 from 9 rats immunised with p15E
(Supplementary Table 1). In a second experiment, 4 rats were im-
munised with p15E. However, in this experiment the preimmune sera
showed binding antibodies against p15E (Fig. 2A, lane 10, Fig. 2C) and
neutralising activity. In all cases the GAPDH-speciﬁc real-time PCR
showed absence of cytotoxic activity in the sera. Unexpectedly, also
the preimmune sera from guinea pigs and mice showed reduction of
PERV infection. Since this unspeciﬁc activity could not be eliminated
by puriﬁcation of IgGs (data not shown), the neutralising activity
of the immune sera from these mice, guinea pigs and rats in the
second experiment could not be determined, despite the fact that
this assay was successfully applied in the case of goats and rats in the
ﬁrst experiment.
Epitope mapping of the generated antibodies
To analyse the epitopes of the PERV-speciﬁc antibodies, an epitope
mapping was performed using linear 15-mer peptides overlapping by
12 amino acids and corresponding to the entire p15E (Fig. 4A). Two
main epitopes were identiﬁed when the serum from goat #16 was
Fig. 4. (A) Example of an epitope mapping: serum from mouse #3, immunised with p15E. 15-mer peptides overlapping by 12 residues were ﬁxed on the membrane, stained
peptides were identiﬁed and epitopes determined. (B) Localisation and sequence of the peptides used for BIAcore analysis. (C) Summary of the epitopes recognised by each immune
serum. All animals were immunised with recombinant p15E. The sequences of p15E of PERV-A, PERV-B, PERV-C and FeLV are shown and groups of epitopes were framed:
E1 according to the epitope recognised by goat serum 20, E2a, E2b according to the epitopes identiﬁed in the case of FeLV (Langhammer et al., 2006). For comparison the sequence
of gp41 of HIV-1 and the epitopes recognised by the monoclonal antibodies 2F5 and 4E10 are shown (Zwick et al., 2001). (D) Schematic presentation of the localisation of
epitopes recognised by neutralising antibodies induced by immunising goats and rats with p15E of PERV, goats and rats with p15E of FeLV (Langhammer et al., 2005) and by
monoclonal broadly neutralising antibodies isolated from HIV-infected individuals (Zwick et al., 2001). FP—fusion peptide, NHR—N-terminal helical region, CHR—C-terminal helical
region, TM—transmembrane region.
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et al., 2003); one epitope, E1, was located in the FPPR and the other,
E2, in the MPER. All goat sera recognised the sequence GPQQL in the
E1 region. Goat serum #346 showed an additional epitope localised
in the immunosuppressive domain (Tacke et al., 2000). In two cases
(goat sera #346 and #355), an arginine rich epitope (ERLERRR) was
identiﬁed in the MPER (Fig. 4C). Whereas goat sera 16 and 20
recognised only one epitope in each domain, goat serum 346, 355 and
4 out of 9 rat sera recognised two epitopes, E2a and E2b, in the MPER.
Most of the E2b epitopes contained the sequence FEGWFN. Whereas
all rat, mice and guinea pig sera recognised epitopes in the MPER, only
5 of them recognised a sequence in the FPPR (Fig. 4C). Most im-
portantly, the localisation of the epitopes is similar in the case of sera
from goats and rats immunised with p15E of PERV and FeLV, the E2bepitope FEGWFN is identical in both viruses and corresponds in
localisation and sequence to the epitope NWFNIT in gp41 of HIV-1
recognised by the broadly neutralising antibody 4E10 (Fig. 4C).
Speciﬁcity of the neutralising activity
To demonstrate the speciﬁcity of the neutralising activity,
inhibition experiments were performed using recombinant gp70,
and synthetic peptides corresponding to the p15E epitopes. When
goat serum 62, speciﬁc for gp70, was incubated with recombinant
gp70, a dose-dependent inhibition of the neutralisation was observed
(Fig. 5). To investigate whether antibodies against both epitopes
described for the goat sera immunised with p15E were involved in
neutralisation, serum 355was incubated with peptides corresponding
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domain as a control. Only the E2 peptide inhibited neutralisation
signiﬁcantly, indicating that the neutralising antibodies were directed
mainly against the MPER of p15E. In the case of HIV-1 neutralising
antibodies such as 2F5 and 4E10 also bind only to the MPER of gp41
(Zwick et al., 2001).
Surface plasmon resonance (SPR) analysis conﬁrms antibody binding
To conﬁrm binding of the sera to the epitopes identiﬁed by epitope
mapping, a second method, SPR analysis using a BIAcore X100 was
used. Two peptides, E1(484–505) GTAALITGPQQLEKGLSNLHRI) and
E2(583–604) (EREADQGWFEGWFNRSPWMTTL, epitopes recognised
by goat serum 20 in bold) (Fig. 4B), and their randomised controls
were used. SPR analysis showed that binding of the antibodies to the
MPER peptide is typical of well-binding antibodies, such as the
broadly neutralising antibody 2F5 to its epitope (Fiebig et al., 2009)
(Fig. 6A). Whereas goat serum 355 binds nearly equally to E1(484–
505) and E2(583–604) peptides, goat sera 16 (4.1 fold), 20 (3.6 fold)
and 346 (1.7 fold) showed a stronger binding to the MPER-derived
peptide E2 if compared to the FPPR-derived peptide E1 (Fig. 6B). Sera
from four guinea pigs immunisedwith p15E alone (columns 1, 2) or in
combination with gp70 (columns 3, 4) showed binding to the MPER-
derived E2(583–604) in the BIAcore analysis. Sera of guinea pigs
immunised with gp70 alone (column 5, 6) and control sera (column
7,8) showed as expected no reactivity speciﬁc for E1 or E2 (Fig. 6C).
Sera from three out of four rats immunised with p15E and two out
of four immunised with a mixture of p15E and gp70 showed binding
to the MPER-derived peptide E2 (Fig. 6D).
Immune sera react with PERV on the cell surface
To elucidate the possible mechanism of neutralisation, the locali-
sation of the epitopes recognised by thep15E-speciﬁc serawas analysed
by immunoﬂuorescence using non-permeabilised 293 cells infected
with PERV/5°. Uninfected 293 cells were neither stained by the
preimmune serum nor by the immune serum of goat 355 (Fig. 7A, B).In contrast, immune serum 355 reacted with larger virus accumula-
tions located on the surface of PERV infected 293 cells (Fig. 7C, D).
Such accumulation of PERV on the cell surface has been demonstrat-
ed by scanning electron microscopy (Karlas et al., 2010). Preimmune
sera did not react with PERV producing 293 cells. These data indicate
Fig. 7. Fluorescence microscopy showing absence of binding of preimmune serum with PERV infected 293 cells (A), and of neutralising goat serum 355 with uninfected cells (B),
as well as binding of immune 355 serum with infected 293 cells (C, D); as secondary antibody an anti-goat FITC antibody was used. Immunoﬂuorescence was analysed by confocal
laser microscopy (A, C) and on an Axioskop (B, D).
83D. Kaulitz et al. / Virology 411 (2011) 78–86that the epitopes in the virus protein p15E were exposed on the cell
surface.
Discussion
Here we report for the ﬁrst time induction of antibodies neu-
tralising PERV by immunisation with the surface envelope proteins
and extend our studies on induction of neutralising antibodies by
immunising with the transmembrane envelope protein p15E. Most
interestingly, one of the epitopes recognised by the anti-p15E sera
induced in all species (FEGWFN) is localised in the MPER in a posi-
tion similar to that of the monoclonal antibody 4E10 broadly neu-
tralising HIV-1 in gp41 (NWFNIT, identical amino acids in bold). 4E10
broadly neutralises isolates of different clades of HIV-1 (Binley et al.,
2004). Sera of all animals immunised with p15E of PERV recognised
epitopes in the MPER as well as in the FPPR. Similar epitopes were
foundwhen goats, rats, mice, and cats had been immunisedwith p15E
of FeLV (Langhammer et al., 2005, 2006) (Fig. 4D) aswell as with p15E
of the koala retrovirus (KoRV) (unpublished data).
According to a recent model of intramolecular conformational
changes in the transmembrane envelope protein during virus in-
fection (for review see Melikyan, 2008), it is very likely that E1 in the
FPPR and E2 in the MPER are in close proximity after the interaction
of the N-terminal and the C-terminal helical regions. Using SPR
analyses, an interaction between peptides corresponding to E1 and E2
of gp41 of HIV-1 had been demonstrated, and the binding of the
antibody 2F5 to its epitope in the MPER increased in the presence of a
peptide derived from the FPPR (Fiebig et al., 2009). However, at-
tempts to design an antigen based on gp41 able to induce neutralising
antibodies failed until now since its conformation is unknown.
Using a novel neutralisation assay based on real-time measure-
ment of proviral DNA we successfully demonstrated neutralising
activity in the sera from goats and rats in the ﬁrst experiment. Similarneutralisation assays were developed and applied for HIV-1 (Fiebig
et al., 2009) and HIV-2 (Behrendt et al., 2009). Since there were
neutralising activities in the preimmune and control sera from mice,
guinea pigs, and rats in the second experiment, we were unable to
detect neutralising antibodies in these sera. However, the identical
localisation of the epitopes recognised by these sera and the similarity
in the epitope sequence (Fig. 4C) suggest that the antibodies induced
in these species are neutralising. False-positive neutralising activity in
preimmune and control sera are common and seriously hamper
vaccine development (Denner, 2011).
There is an urgent need to develop antiretroviral vaccines, ﬁrst
of all against HIV-1 and HIV-2 to stop the AIDS pandemic. There is also
a need for a vaccine against human T-lymphotropic leukaemia viruses
(HTLV-1 and -2). Recently, a new gammaretrovirus, XMRV, was
described in patients with prostate carcinoma and chronic fatigue
syndrome (CFS) and in some healthy individuals in the USA, but not in
Europe (for review see Denner, 2010). If this virus is indeed dis-
tributed in the North American population, a vaccine may be required
to eliminate the virus. A vaccine against PERV will be recommen-
dable in case PERV is transmitted after xenotransplantation and
infects humans in vivo.
Although numerous strategies are under development to prevent
PERV transmission, such as inhibition of PERV expression by RNA
interference using transgenic animals expressing PERV-speciﬁc siRNA
(Dieckhoff et al., 2008; Ramsoondar et al., 2009), treatment with
antiretroviral drugs such as azidothymidine (Qari et al., 2001; Shi
et al., 2007; Stephan et al., 2001), a vaccine based on neutralising
antibodies could be useful. These different approaches are aimed to
increase virus safety, but their efﬁcacy and impact on the safety of
xenotransplantation remains to be validated.
Xenotransplantation of porcine cells or organs is a technology that
may be available soon. First clinical trials using insulin producing pig
islet cells are in progress. Worldwide more than 200 patients have
84 D. Kaulitz et al. / Virology 411 (2011) 78–86been treated with pig islet cells or ex vivo with spleen or liver cells
(Paradis et al., 1999). Although transmission of PERV was neither
observed in these ﬁrst clinical trials (Elliott et al., 2000; Heneine et al.,
1998; Valdes-Gonzalez et al., 2010), nor in animal models of
xenotransplantation (Winkler et al., 2005; Moscoso et al., 2005;
Switzer et al., 2001), the risk of a xenosis can by no means be
excluded. PERV inoculation experiments in small animals and non-
human primates showed either absence of virus transmission (Specke
et al., 2009, 2001b, 2002), or false-positive transmission due
to pseudotyping of PERV with murine retroviruses in mice (Deng
et al., 2000; van der Laan et al., 2000; Clémenceau et al., 2002; Martina
et al., 2005) or transient expression at a very low level (Argaw et al.,
2004; Popp et al., 2007). However, when mice which do not have a
receptor for PERV (Ericsson et al., 2003) were inoculated with cell-
free virus, no transmission was observed (Irgang et al., 2005). A
detailed and comprehensive overview of all clinical and preclinical
xenotransplantation studies as well as of the PERV inoculation
experiments are given in (Denner et al., 2009) These data indicate
absence of productive replication in vivo despite infection in vitro, in
cell lines of different species.
Methods
Cloning and puriﬁcation of p15E and gp70
Two antigens were used for immunisation, (i) the ectodomain of
p15E of PERV-A, expressed and puriﬁed as described (amino acids
488–596, accession number HQ688786) (Fiebig et al., 2003), and (ii) a
recombinant protein corresponding to gp70 of PERV-A (amino acids
49–487, accession number HQ688785). The sequence was ampliﬁed
using RNA from PK15 cells and the primers gp70-for-EcoRI and gp70-
rev-SalI 5' (Table 1). The cloned sequence resembles the sequence of
gp70 of FeLV, used in Leucogen for vaccination (Marciani et al., 1991).
It was cloned into the pET-22b(+) expression vector (Novagen, San
Diego, CA). Protein was expressed in E. coli BL21-CodonPlus(DE3)-RP
(Stratagene, Amsterdam). Synthesis of the hexahistidine-tagged
protein was induced with 0.05 mM isopropyl-D-thiogalactopyrano-
side (IPTG) at 37 °C in LB-medium at OD600 of 0.7. After 3 hours
bacteria were harvested by centrifugation at 8000g and disrupted by
sonication. The insoluble recombinant protein was pelleted by
centrifugation at 25,000g for 30 min, the pellet was resolved in 6 M
GuHCl buffer, puriﬁed by metal chelating afﬁnity chromatography
using Ni-NTA (Qiagen), and the protein was dialysed against PBS and
characterised by SDS-PAGE and Western blotting.
Immunisation, antisera and puriﬁcation of immunoglobulins
Goats were immunised with 500 μg antigen, Wistar rats with
150 μg, Balb/c mice with 50 μg, rabbits with 250 μg, 340 μg or 170 μg
and guinea pigs (rats, mice and rabbits were obtained from Charles
River) with 200 μg p15E, gp70 or a mixture of both proteins
intramuscularly and subcutaneously. Antigens were emulsiﬁed in
complete Freund's adjuvant. The immune response was boosted byTable 1
Primers and probes.
Primer/probe Sequence 5′–3′
hGAPDH-for GGCGATGCTGGCGCTGAGTAC
hGAPDH-rev TGGTCCACACCCATGACGA
hGAPDH-probe HEX-TTCACCACCATGGAGAAGGCTGGG-BHQI
PERV-gag-for TCCAGGGCTCATAATTTGTC
PERV-gag-rev TGATGGCCATCCAACATCGA
PERV-gag-probe FAM-AGAAGGGACCTTGGCAGACTTTCT-BHQ1
Gp70-for-EcoRI AGAATTCG-AGCCCGAACTCCCATAAACCC
Gp70-rev-SalI AAAGTCGAC-GGCAGCCGTTCCTGTTCCCsecond and third immunisations after periods of 2 and 5 weeks using
incomplete Freund's adjuvant. Immunoglobulins were puriﬁed using
2 M ammonium sulphate; IgGs were puriﬁed using the Ab SpinTrapTM
kit (GE Healthcare) as recommended by the manufacturer.Peptides
Biotinylated peptides E1(484–505) GTAALITGPQQLEKGLSNLHRI,
E2(583–604) EREADQGWFEGWFNRSPWMTTL (Fig. 4B), E1 rando-
mised ALRLGQELISGHNAPIKTQTLG and E2 randomised
TWPGEFWRSTNMLDWEQARFGE were synthesised by Genaxxon
BioScience GmbH, Biberach, Germany. For the inhibition experi-
ments modiﬁed E1 and E2 peptides (AALITGPQQLEKGLSNLHRICKKK;
KKKCCREREADQGWFEGWFNRSPWM) as well as a peptide
(VVLQNRRGLDLLFLKEGGL) corresponding to the immunosuppressive
domain, synthesised by Jerini, Berlin, Germany, were used.Western blot, ELISA
Western blot and ELISA were performed as described before
(Tacke et al., 2001) using the recombinant proteins gp70 and p15E, or
lysates of puriﬁed PERV preparations, respectively. In ELISA 0.5 μg/
well recombinant proteins and in Western blot assays 1 μg of virus
preparation was used; sera were diluted 1:100 to 1:250. A secondary
antibody labelled with HRP was used for ECL detection.Epitope mapping
The entire p15E of PERV (130 amino acids) was synthesised as a
cellulose-adsorbed peptide spot library of 15-mer peptides over-
lapping by 12 amino acids (JPT Peptide Technologies, Germany) using
a standard protocol of the supplier. Sera were diluted 1:1000 and
binding was detected using a chemiluminescence detection solution
(ECL, Amersham Pharmacia Biotech).Real-time PCR
For quantiﬁcation of PERV proviral DNA the primers gag-for and
gag-rev located in the gag gene and a speciﬁc PERV-gag probe
(Table 1) were used in a duplex real-time PCR. The reference gene
GAPDH was ampliﬁed with the primers GAPDH-for and GAPDH-rev
and quantiﬁed using an hGAPDH-probe. The 22 μl reaction mixture
consisted of 1× PCR buffer with 1.5 mM MgCl2, 0.5 μM each of dATP,
dCTP, dGTP, dTTP, 5 pmol of each primer, 5 pmol of probe, 1.25 U
AmpliTaq Gold® polymerase and 3 μl lysate. The thermal cycling
conditions used were 10 minutes at 95 °C followed by 50 cycles of
1 minute at 95 °C, 1 minute at 59 °C and 30 seconds at 72 °C in a
Stratagene MX4000 machine. Efﬁcacy was calculated by measuring
ten fold serial dilutions of a subcloned hGAPDH PCR-fragment and the
molecular clone PERV-A 14/220, kindly provided by Y. Takeuchi.Direction Location Accession no.
+ 365..385 AF261085
− 495..513 AF261085
+ 407..430 AF261085
+ 1213..1232 AJ293656
− 1289..1308 AJ293656
+ 1244..1267 AJ293656
+ 6329..6349 AJ293656
− 7627..7645 AJ293656
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Two types of neutralisation assays were performed using virus-
containing cell-free supernatants produced by human embryonic
kidney 293 cells infected with PERV/5°. This virus is a PERV-A/C
recombinant repeatedly passaged on human cells which was asso-
ciated with elevated titres and genetic alterations in its long termi-
nal repeats (LTR) (Denner et al., 2003). In addition, PERV-B kindly
provided by D. Onion, was also used. 100 μl uninfected 293 cell
(1.5×105/ml) were seeded in 96well plates and incubated for 4 hours
at 37 °C in 5% (v/v) CO2. Sera were decomplemented by heat
inactivation (30 min at 56 °C) and 20 μl were mixed with 80 μl of a
PERVdilution, incubated for 30 min at 37 °C and added to the 293 cells.
Virus dilutions resulting in stable Ct values (25 to 27) were considered
as optimal for the neutralisation assay. After incubation for 72 h at
37 °C cells were examined by light microscopy for viability and the
mediumwas removed. Cells were lysed by heating at 95 °C for 30 min,
freezing at−20 °C for 6 hrs, and incubationwith lysis buffer (nuclease
free water containing 0.2 mg/ml proteinase K and 10% (v/v) 10×PCR-
buffer) at 60 °C for at least 3 hrs. Proteinase K was heat inactivated
(30 min at 95 °C). In the ﬁrst assay proviral DNA was measured by a
simple PCR, virus was diluted in the absence and presence of a dilu-
tion of the immune serum of 1:10 and the TCDI50 was determined. In
the second assay proviral DNA was quantiﬁed by real-time PCR (see
below), 3 μl of the lysate were used in the duplex real-time PCR. To
inhibit neutralisation, recombinant gp70 or synthetic peptides were
diluted and incubated with immune serum for 20 min and both with
the virus another 20 min.
Calculation of neutralisation efﬁcacy
In the assay based on real-time PCR, neutralisation was deﬁned as
reduction of provirus integration in the presence of immune serum.
The ct values of GAPDH were identical in all samples, indicating
absence of toxic effects of the sera. In Fig. 3 neutralisation was ex-
pressed as increase of PERV speciﬁc ct values (the higher the ct value
in the real-time PCR the lower the provirus load). In Fig. 5 percent
of neutralisation was calculated as (ct value of PERV−ct value of
GAPDH) in the presence of serum− (ct value of PERV−ct value of
GAPDH) in the absence of serum (ΔΔct) and the 2ΔΔCtmethod (Livak
and Schmittgen, 2001), % neutralisation (NT) was calculated as
NT=100–100/2ΔΔCt. A ΔCt of at least 2, which corresponds to a
provirus reduction of 75%, was deﬁned as a signiﬁcant difference in
provirus integration.
Surface plasmon resonance (SPR) analysis
SPR analysis was performed using a BIAcore X100 (GE Healthcare,
Waukesha, Wisconsin, USA). Two streptavidin (SA) chips (GE
Healthcare) were generated. The ﬁrst chip was coated on ﬂow cell
(Fc) 2 with 1200 resonance units (RU) of the biotinylated sequence
E1(484–505), and on Fc 1 with 1200 RU of the biotinylated E1-
randomised peptide. Fc 2 of the second chip was coated with E2(583–
604) and Fc 1 with the randomised E2 peptide, respectively. The
immune sera were tested undiluted. As running buffer 1× HBS-EP
+buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0,05% Surfactant
P20, pH 7,4; GE Healthcare) containing 1 M urea was used. The
binding time for the sera to its ligand was 60 sec and the dissociation
time 180 or 240 sec. For the regeneration of the chips 50 mM glycine/
HCl, pH 1.5 (in the case of guinea pig sera pH 2.0) was used. All
binding analyses were performed at 25 °C at a ﬂow rate of 10 μl/min.
Immunoﬂuorescence
PERV/5° producing and uninfected 293 cells were grown on
culture dishes with a hydrophobic membrane (Petriperm, Heraeus),washed with PBS and ﬁxed with 2% paraformaldehyde for 2 h. After
washing with PBS, the membrane was cut in small pieces. Cells
were blocked with PBS supplemented with 0.1% gelatine and 1%
rabbit serum. Preimmune and serum of goat 355 immunised with
p15E were tested at a dilution of 1:500. After washing the cells were
incubated with FITC-labelled rabbit anti-goat IgG (Sigma) at a dilution
of 1:160. Finally, cells were embedded in Moviol 4-88 (Roth) and
0.1 μg/ml Bisbenzimide H 33258 (Sigma) solution, and the surface
ﬂuorescence was analysed by ﬂuorescence microscopy (Axioskop2,
Axiovision Rel. LE 4.5 and CLSM Mikroskop 510 META, Carl Zeiss AG
Oberkochen, Germany)
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.032.
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